Abstract
A novel class of therapeutic agents based on nucleic acids has emerged and shown very promising pre-clinical results, named small interfering RNAs (siRNAs) and microRNAs (miRNAs). siRNAs are small RNA duplexes capable of silencing undesired (i.e., mutant, exogenous or aberrant) gene expression with high specificity through a mechanism known as RNA interference. These agents have called special attention to neuroscience since they have been used to experimentally treat a variety of neurological diseases with distinct etiologies such as viral, prions, genetic disorders and others. siRNAs have also been used in other scenarios as: drug-receptor blockage, inhibition of pain signaling and regulation of behavior. Although in a very initial stage, miRNAs also promise novel therapeutic approaches. In this review article we intend to introduce clinicians and researchers to the novel field of si- and miRNA-mediated gene silencing strategies, its history, use in cell and animal models, delivery methods, current status and possible applications in future clinical practice.
Central Nervous System Agents in Medicinal Chemistry
Title: Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Volume: 8 Issue: 2
Author(s): Tiago Campos Pereira and Iscia Lopes-Cendes
Affiliation:
Abstract: A novel class of therapeutic agents based on nucleic acids has emerged and shown very promising pre-clinical results, named small interfering RNAs (siRNAs) and microRNAs (miRNAs). siRNAs are small RNA duplexes capable of silencing undesired (i.e., mutant, exogenous or aberrant) gene expression with high specificity through a mechanism known as RNA interference. These agents have called special attention to neuroscience since they have been used to experimentally treat a variety of neurological diseases with distinct etiologies such as viral, prions, genetic disorders and others. siRNAs have also been used in other scenarios as: drug-receptor blockage, inhibition of pain signaling and regulation of behavior. Although in a very initial stage, miRNAs also promise novel therapeutic approaches. In this review article we intend to introduce clinicians and researchers to the novel field of si- and miRNA-mediated gene silencing strategies, its history, use in cell and animal models, delivery methods, current status and possible applications in future clinical practice.
Export Options
About this article
Cite this article as:
Pereira Campos Tiago and Lopes-Cendes Iscia, Novel Nucleic Acid-Based Agents: siRNAs and miRNAs, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152408784533932
DOI https://dx.doi.org/10.2174/187152408784533932 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Sialic Acid and the Central Nervous System: Perspectives on Biological Functions, Detection, Imaging Methods and Manipulation
CNS & Neurological Disorders - Drug Targets Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Antitumor Activity and Structure-Activity Relationship of Diterpenoids with a Dehydroabietyl Skeleton
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Chemical and Biological Technology for In Vivo and Molecular Imaging)
Current Topics in Medicinal Chemistry Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Current Neuropharmacology Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells In Vitro
Anti-Cancer Agents in Medicinal Chemistry PET Tracers for Mapping Adenosine Receptors as Probes for Diagnosis of CNS Disorders
Central Nervous System Agents in Medicinal Chemistry Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions
Current Gene Therapy A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design The Possibility of Novel Antiplatelet Peptides: The Physiological Effects of Low Molecular Weight HSPs on Platelets
Current Pharmaceutical Design